- 1 COVID-19 vaccination coverage and hesitancy among Australians with disability and long-
- 2 term health conditions
- 3
- 4 Zoe Aitken
- 5 Disability and Health Unit, Centre for Health Equity, Melbourne School of Population and
- 6 Global Health, The University of Melbourne
- 7
- 8 Eric Emerson
- 9 Institute for Health Research, Lancaster University
- 10
- 11 Anne Kavanagh
- 12 Disability and Health Unit, Centre for Health Equity, Melbourne School of Population and
- 13 Global Health, The University of Melbourne
- 14
- 15
- 16 Abstract

17 Background: COVID-19 vaccination is the cornerstone of managing Australia's COVID-19

- 18 pandemic and the success of the vaccination program depends on high vaccination coverage.
- This paper examined differences in COVID-19 vaccination coverage and vaccine hesitancy
   for people with disability, long-term health conditions, and carers subgroups that were
- 21 prioritised in the vaccination program.

22

Methods: Using data from 2,400 Australians who participated in two waves of the Taking the Pulse of the Nation survey in April and May 2021, we described vaccination coverage and hesitancy among people with disability, severe mental health conditions, severe long-term health conditions, frequent need for assistance with everyday activities, and carers, disaggregated by age group and gender.

28

Findings: Vaccination coverage was estimated to be 8.2% in the sample overall and was similar for people with disability, those with frequent need for assistance, and carers. It was higher for people with severe long-term health conditions (13.4%) and lower for people with severe mental health conditions (4.3%). Vaccine hesitancy was high overall (35.6%) and was similarly high across the priority groups.

34

Interpretation: This study highlights the lack of a difference in vaccination coverage and vaccine hesitancy for people with disability, long-term health conditions, and carers compared to the general population. Sub-optimal vaccination coverage for people in the priority population groups leaves many people at significant risk of serious disease or death if exposed to COVID-19, particularly in light of the easing of disease-control restrictions across Australia and the emergence of new COVID-19 variants.

41

42 Funding: National Health and Medical Research Council

- 43
- 44

## 45 Introduction

46 COVID-19 vaccination is the cornerstone of managing the COVID-19 pandemic. The 47 success of any vaccination program depends on high vaccination coverage and acceptance. 48 Across the world, countries implemented different strategies for the prioritisation of COVID-49 19 vaccination. The World Health Organization (WHO) developed guidelines for the 50 prioritisation of vaccination among groups according to their risk of acquisition and 51 transmission of COVID-19 (e.g., health care workers providing direct care) and risk of 52 serious disease or death if infected by COVID-19 (e.g., older people, organ transplant recipients).<sup>1</sup> WHO also recommended that the levels of community transmission in a country 53 54 should also guide vaccine distribution.<sup>1</sup>

55

56 In Australia, the Commonwealth government has been responsible for the procurement and 57 distribution of COVID-19 vaccines and the policy settings, although there have been some 58 variations between States and Territories in the rollout to different groups. The 59 Commonwealth government prioritised a range of groups in Phase 1a, which commenced on 60 22 February 2021 and Phase 1b which commenced on 22 March 2021 (Table 1). People with 61 long-term health conditions including serious mental illness, people with intellectual disability and people who required assistance with activities of daily living were prioritised.<sup>2</sup> 62 63 These groups also included workers providing support in aged-care or to people with 64 disability, as well as informal carers who provide unpaid support to people who needed 65 assistance with activities of daily living.

- 66
- 67
- 68

# 70 Table 1 Phase 1a and 1b priority groups

Phase 1b
People with long-term health conditions
People with disability
Carers
People aged 70 years and older
Aboriginal and Torres Strait Islander Peoples
aged 56 years and older
Other health care workers
Critical and high-risk workers

71

At the start of 2022, Australia had high COVID-19 vaccination coverage, ranked 15<sup>th</sup> 72 73 globally in terms of the proportion of the population vaccinated according to the Johns 74 Hopkins Coronavirus Resource Centre Vaccine Tracker.<sup>3</sup> By mid-February 2022, 94.1% of people aged 16 years and over had received two COVID-19 vaccine doses.<sup>4</sup> However, the 75 76 vaccination coverage was substantially lower in some subgroups of the population at highest 77 risk of COVID-19 infection and morbidity, such as Aboriginal and Torres Strait Islander Peoples (76.6%) and National Disability Insurance Scheme (NDIS) participants (86.1%),<sup>4</sup> 78 79 demonstrating large inequalities in vaccination coverage. Therefore, despite prioritising 80 people at highest risk, some priority groups have sub-optimal vaccination coverage which poses a threat to individual and population immunity.<sup>5</sup> 81

82

83 People with disability and long-term health conditions are at high risk of serious disease or 84 death if infected with COVID-19 due to comorbidities, living conditions, behavioural factors 85 and socio-economic deprivation and may have higher risk of infection and transmission because of their need for care or assistance and increased likelihood of living in congregate 86 care settings.<sup>6,7</sup> But there is a lack of data describing COVID-19 vaccination rates for people 87 88 with disability and long-term health conditions because disability data are not routinely 89 collected in Australia. Data from government and media reports from mid-2021 showed that 90 there were significant delays in the rollout of the vaccine among people living in aged-care and disability residences and the workers who support them.<sup>8-10</sup> Since 21 January 2022, data 91 have been routinely reported on vaccination coverage for NDIS participants,<sup>11</sup> demonstrating 92 93 lower vaccine coverage compared to the general population, but this only represents 10% of 94 Australians with disability. There is a lack of data on vaccination coverage for the 90% of 95 Australians with disability who are not eligible for the NDIS.

96

97 There are several potential causes of low vaccination coverage for people with disability 98 including physical availability of vaccines, geographic accessibility, availability of accessible 99 information about vaccine availability and eligibility, and vaccine hesitancy.<sup>5</sup> At the start of the vaccination program, there was a lack of supply – a problem that intensified after the 100 101 Commonwealth government recommended that the Comirnaty (Pfizer/BioNTech) COVID-19 vaccine was used for people under 50 years on 8<sup>th</sup> April 2021 and then under 60 years on 16<sup>th</sup> 102 103 June 2021 because of the risk of Thrombosis with Thrombocytopenia Syndrome (TTS) associated with the Vaxzevria (AstraZeneca) COVID-19 vaccine in younger age-groups.<sup>12,13</sup> 104 Vaccine hesitancy, the delay in the acceptance or refusal of vaccines.<sup>5,14,15</sup> is also a likely 105 cause of inequalities in vaccination coverage. 106

107

108 Australian research has demonstrated relatively high levels of vaccine hesitancy in the population compared to similar countries.<sup>16</sup> An Australian survey conducted in January 2021 109 110 before the vaccination program was implemented, found that only 44% of Australians 111 reported that they would definitely get vaccinated, with 35% reporting they would probably 112 get vaccinated, 8% reporting they would probably not get vaccinated, and 13% reporting they would definitely not get vaccinated.<sup>17</sup> More recent data from a longitudinal survey 113 114 investigating the impacts of the COVID-19 pandemic on Australian households which 115 collected data on disability and included questions about vaccine hesitancy in five waves of 116 the survey between December 2020 and July 2021 found that levels of vaccine hesitancy were very similar between people with and without disability, though vaccine hesitancy was 117 higher for people with psychosocial disability.<sup>18</sup> 118

119

120 Australia experienced a surge in COVID-19 infections at the end of 2021 alongside the 121 easing of disease-control restrictions and the emergence of the Omicron variant, which 122 highlights the ongoing need for high COVID-19 vaccination coverage. Despite high 123 vaccination coverage in the population overall, waning vaccine immunity and sub-optimal 124 vaccination coverage in some subgroups of the population pose a threat to individual and 125 population immunity.<sup>5</sup> Understanding inequalities in vaccine coverage and attitudes towards 126 vaccine hesitancy is important for tailoring vaccination programs and evidence-informed and community-engaged responses to vaccine hesitancy to different subgroups.<sup>19,20</sup> It is also 127 critical for understanding the potential impacts of easing restrictions on severe outcomes 128

associated with COVID-19 infection, which will be distributed inequitably across differentsubgroups of the population.

131

132 This paper fills a gap in our knowledge about vaccination coverage and vaccine hesitancy 133 among people with disability and long-term health conditions, and carers in Australia with 134 the aim of identifying groups who require better targeting to improve vaccination coverage 135 and understanding the causes of sub-optimal vaccination coverage. Using data from 2,400 136 Australians who participated in Taking the Pulse of the Nation survey in April and May 137 2021, at the start of the COVID-19 vaccination program, we describe vaccination coverage 138 and hesitancy among people with disability, people who reported living with a severe mental 139 health condition, a severe long-term health condition, and those requiring frequent assistance 140 with everyday activities. We also report vaccination coverage and hesitancy for people who 141 provide paid or unpaid care to someone in one of the priority groups.

142

### 143 Methods

144 We used data from Taking the Pulse of the Nation (TTPN), a repeated cross-sectional survey 145 which has been conducted every two weeks since April 2020 by the Melbourne Institute: 146 Applied Economic & Social Research at the University of Melbourne. The survey was 147 implemented by a market research company Oz Info as a telephone or online interview, 148 collecting data from 1200 people at each wave to track Australians' expectations and 149 attitudes towards the COVID-19 pandemic. The sampling frame was constructed by Oz Info 150 from a diverse set of continuously updated proprietary databases. A stratified sampling 151 design was employed, dividing the population into strata defined by selected characteristics, 152 which were sampled separately to ensure representativeness of the underlying population of interest.<sup>21</sup> The strata were defined according to state of residence (all six states and the 153 154 Australian Capital Territory), location within each state (Greater Capital Area; other), gender 155 (men; women) and age group (18-24; 25-34; 35-44; 45-54; 55-64; 65-75; older than 75 156 years), with weights constructed to ensure the sample in each wave was representative of the 157 underlying population using ABS estimated resident population projections based on the 2016 Census.<sup>22</sup> The TTPN survey was approved by the Human Research Ethics Committee at 158 159 the University of Melbourne (2021-14006-14669-1). The TTPN Survey data are available on 160 application to the Melbourne Institute: Applied Economic & Social Research at the 161 University of Melbourne.

162

163 This analysis used data from two waves of the survey conducted between 19 and 25 April 164 and between 10 and 14 May 2021 in which additional questions were included about 165 disability, long-term health conditions and caring responsibilities. At this stage of the 166 pandemic, people over the age of 50 years and people in high priority groups (and their 167 carers) were eligible to receive the vaccine (Table 1). In these two waves of the survey, a 168 question was included about presence of disability, defined as "a long-term health condition, 169 impairment or disability that restricts you in your everyday activities and has lasted (or is 170 likely to last) for 6 months or more". Additional questions were included to identify whether 171 people had a severe mental health condition, a severe long-term health condition, or required 172 frequent assistance with everyday activities (e.g., eating, dressing, mobility), to align with the 173 vaccine priority group eligibility criteria. A question was also included to identify people 174 who provided care, help or assistance, either paid or unpaid, to people in the high priority 175 groups. Survey participants could tick multiple responses to these questions. For all 176 questions, responses "don't know" were recoded to missing.

177

178 Information on vaccination and vaccine hesitancy was recorded in the survey. Participants 179 were asked if they were "willing to have the COVID-19 vaccine" with possible responses 180 listed as "I have had it already", "yes", "no", and "don't know". People were identified as 181 being vaccinated if they responded that they had had the vaccine. Therefore, vaccination 182 coverage represents people who have had at least one dose of the vaccine. People were 183 identified as being vaccine hesitant if they responded "no" or "don't know", including both vaccine refusers and those who may choose to delay, in accordance with the definition 184 derived by the SAGE Working Group on Vaccine Hesitancy.<sup>23</sup> People were identified as not 185 186 vaccine hesitant if they responded "yes" or were already vaccinated. We included people who 187 were vaccinated in the non-vaccine hesitant group to ensure valid comparisons of vaccine 188 hesitancy between subgroups of the population, independent of the proportion of people who 189 had been vaccinated.

190

Population subgroups of interest included age groups (18-64 years; 65 years and above) andgender (men; women).

193

We estimated the proportion of the sample who were vaccinated and who were vaccine hesitant, for the whole sample (both waves combined) and for exposure groups of interest (people with disability, severe mental health conditions, severe long-term health conditions,

197 people requiring frequent assistance with everyday activities, and people who were paid or 198 unpaid carers). We disaggregated the results by age group and gender. Results were not 199 presented separately for each wave of the survey due to sample size limitations. The analyses 200 used survey weights, constructed using the most recent Australian Bureau of Statistics 201 estimated resident population projections based on the 2016 Census, stratified by gender, age 202 and location to be representative of the Australian population. Analyses were conducted in 203 Stata/SE 14.2 using the survey commands to account for the survey design characteristics.

204

## 205 Results

The two waves of the survey included 2,400 participants, of which 8.2% were vaccinated and 35.6% were vaccine hesitant (Table 2), comprising 19.1% who reported being unwilling to

208 get the vaccine and 16.5% who were unsure (data not shown).

209

Of the sample, 27.5% of participants had a disability, 10.8% had a severe mental health condition, 19.9% had a severe long term health condition, 5.6% had frequent need for assistance, and 26.4% were paid or unpaid carers. In terms of demographics, 20.2% of the sample were aged 65 years and older, and 51% were women.

214

	n	%
Vaccinated		
Yes	177	8.2
No	2,223	91.8
Vaccine hesitancy		
Yes	854	35.6
No	1,546	64.4
Disability		
No	1,623	69.9
Yes	709	27.5
Missing	68	2.6
Severe mental health condition		
No	2,118	89.2
Yes	282	10.8
Missing	0	0
Severe long term health condition		
No	1,913	80.1
Yes	487	19.9
Missing	0	0
Frequent need for assistance		
No	2,258	94.4
Yes	142	5.6
Missing	0	0
Carer		
No	1,700	71.5
Yes	655	26.4

# 215 Table 2 Characteristics of the sample (n=2,400)

Missing	45	2.1
Age group		
18-64 years	1,942	79.8
65 years and older	458	20.2
Missing	0	0
Gender		
Men	1,200	49.0
Women	1,200	51.0
Missing	0	0

216 Vaccination coverage

217 Compared to the sample overall, the proportion of people who had been vaccinated was 218 higher for people with severe long term health conditions (13.4%), similar for those with 219 disability (8.9%), people in need of frequent assistance with everyday activities (7.1%), and 220 carers (8.9%), and lower for people with severe mental health conditions (4.3%), Table 3). 221 Vaccination coverage was similar for men (9.0%) and women (7.4%), and the patterns across 222 the priority groups were broadly consistent with the sample overall when disaggregated by 223 gender. Vaccination coverage was higher for people aged 65 years and older (30.5%) 224 compared to those aged 18 to 64 years who had very low vaccination coverage (2.6%), even 225 for people in the vaccine priority groups, ranging from 1.2% to 4.2%.

226

227 Table 3 Proportion of the study population who had received at least one dose of COVID-19

228	vaccine,	by	priority	group,	age a	nd gender
-----	----------	----	----------	--------	-------	-----------

	Overall	Disability		Severe long-term health condition	Frequent need for assistance	Carer
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Whole sample	8.2 (6.6, 9.8)	8.9 (6.8, 11.6)	4.3 (2.5, 7.5)	13.4 (9.9, 17.8)	7.1 (3.6, 13.4)	8.9 (6.4, 12.2)
Age						
18-64	2.6 (1.8, 3.6)	3.3 (2.0, 5.5)	2.3 (1.2, 4.5)	4.2 (2.4, 7.4)	1.2 (0.4, 3.8)	4.0 (2.2, 7.1)
65+	30.5 (24.9, 36.8)	27.5 (20.1, 36.4)	42.6 (19.1, 70.0)	32.7 (23.5, 43.4)	26.4 (12.1, 48.2)	26.2 (18.0, 36.5)
Gender						
Men	9.0 (6.9, 11.8)	10.7 (7.5, 15.0)	3.0 (1.2, 7.1)	14.0 (9.9, 19.5)	7.8 (3.2, 17.8)	8.4 (5.6, 12.4)
Women	7.4 (5.6, 9.7)	7.3 (4.8, 11.0)	5.9 (2.8, 11.7)	12.8 (7.9, 20.2)	6.1 (2.2, 16.0)	9.3 (5.8, 14.5)

229

#### 230 Vaccine hesitancy

Overall vaccine hesitancy was high, with 35.6% of the sample estimated to be hesitant to receive the vaccine (Table 4). Vaccine hesitancy was found to be similarly high across the priority groups, ranging from 24.2% for people with frequent need for assistance to 36.1% for people with severe mental health conditions. Vaccine hesitancy was higher for people aged 18 to 64 years (39.7%) compared to those aged 65 years and older (19.3%) and patterns within each age group were similar across the priority groups. There was a slight indication than vaccine hesitancy was higher for women than men (39.9% versus 31.1%).

238

239

240	Table 4 Pro		C 1 / 1	1 . •	1	•	• • • •	1	• • .		
2/10	I ahla / Pro	nortion of	the effective	nonulation	Who word	Vaccina	hacitant	ht/ r	MI Ority	aroun	2000
240	$1 a \cup 0 + 1 \cup 0$	юлион от	une study	DODUIATION	WHO WULL	vaccinc	познані.	ואינו	<i>I</i> IUIIU	Proub.	age

### and gender

	Overall	Disability	Severe mental health condition	Severe long-term health condition	Frequent need for assistance	Carer
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Whole sample	35.6 (33.2, 38.0)	) 30.3 (26.3, 34.7)	36.1 (29.4, 43.5)	27.7 (23.0, 33.0)	24.2 (16.6, 33.8)	30.7 (26.5, 35.2)
Age						
18-64	39.7 (37.0, 42.4	) 34.7 (30.0, 39.8)	37.4 (30.4, 45.0)	32.9 (26.9, 39.6)	27.5 (18.5, 38.9)	34.3 (29.4, 39.6)
65+	19.3 (15.3, 24.1)	) 15.7 (10.6, 22.8)	12.3 (2.9, 39.1)	16.7 (11.0, 24.6)	13.4 (5.0, 31.2)	18.0 (11.8, 26.4)
Gender						
Men	31.1 (27.9, 34.5	) 28.1 (22.6, 34.4)	30.3 (21.3, 41.0)	27.1 (20.4, 35.0)	25.6 (14.9, 40.3)	22.8 (17.5, 29.1)
Women	39.9 (36.5, 43.4	) 32.3 (26.7, 38.6)	42.8 (33.1, 53.1)	28.2 (21.8, 35.6)	22.5 (13.6, 34.9)	36.3 (30.3, 42.8)

<sup>242</sup> 

### 243 **Discussion**

244 The findings of this study suggest that vaccination coverage was similar between people in 245 the overall sample and the majority of the priority groups examined in this study, including 246 people with disability, people with frequent need for assistance and people who were carers. 247 There was some evidence that vaccination coverage was higher for people with severe long-248 term health conditions and lower for people with severe mental health conditions. 249 Vaccination coverage was strikingly low for younger people in all priority groups. Given that 250 people in these priority groups were eligible to receive the vaccine at the time of the survey, 251 the lack of difference in vaccination coverage between young people in the priority groups 252 and the overall sample is surprising and of concern.

253

Despite people with disability being prioritised for vaccination, the Royal Commission hearing in May 2021 highlighted the low rates of vaccination for people with disability.<sup>24</sup> The results of this study were consistent with the findings of the Royal Commission, indicating low vaccination coverage and little evidence of a difference in vaccination coverage for people with disability and long term health conditions compared to the overall sample.

259

Our study found that vaccination coverage was higher for people aged 65 years and older compared to those aged 18 to 64 years. Older adults aged 70 years and older became eligible for vaccination in phase 1b, which explains the higher coverage among older people in the sample, driven by age-based eligibility. This suggests the presence of additional barriers to achieving high vaccination coverage for people with disability and long-term health conditions for whom eligibility for vaccination did not translate into higher vaccination coverage.

267

268 We found evidence of high levels of vaccine hesitancy overall with more than one in three 269 people in the sample reporting that they were hesitant to receive a COVID-19 vaccine. There 270 were high levels of vaccine hesitancy for people in the priority groups, particularly for young 271 people, despite their elevated risk of serious illness or death if they contracted COVID-19. It 272 is important to note that data for the first of the two waves of the survey were collected just 273 after the change in the Commonwealth government recommendation that people under 50 274 years were to receive the Cominraty (Pfizer/BioNTech) vaccine rather than the Vaxzevria 275 (AstraZeneca) vaccine because of the risk of TTS. This announcement may account, in part, 276 for the elevated vaccine hesitancy reported in this study, particularly for young people. 277 Indeed, vaccine hesitancy in the first wave for which data were available on priority groups 278 was estimated to be 39% overall, notably higher than previous and subsequent waves of the 279 TTPN survey where vaccine hesitancy was 32% on average, ranging from 29% to 35%. The 280 estimates of vaccine hesitancy are consistent in magnitude with statistics published by the 281 government which suggest that vaccine hesitancy in Australian adults peaked in April and May 2021 and then gradually declined.<sup>25</sup> Given Australia's current high vaccination rates, 282 283 vaccine hesitancy at the start of the vaccination program has not translated into vaccine 284 refusal for a large proportion of the population. However, data are not currently available on 285 the trajectory of vaccination uptake (and vaccine hesitancy) for people with disability and 286 long-term health conditions, which may be different to the overall population.

287

288 Given the lack of difference in vaccine hesitancy between people with disability and long-289 term health conditions and the overall sample, it is unlikely that the low vaccination coverage 290 for people with disability and long-term health conditions is due to increased vaccine 291 hesitancy. Reports from disability organisations and media have suggested that people with 292 disability experienced multiple barriers, including problems securing appointments, lack of 293 accessible information about eligibility and availability of vaccines, and finding accessible vaccination clinics.<sup>26,27</sup> The lack of research examining reasons for low vaccination coverage 294 295 is an important evidence gap, and important to address for COVID-19 vaccination but also 296 for other vaccines.

297

Our study had a number of strengths. This is the first study to examine vaccination coverage and hesitancy for people with disability and long-term health conditions in Australia, using definitions aligning closely with the vaccine priority groups. The sample was large enough to

301 identify people in all the priority groups of interest, including analyses disaggregated by age 302 group and gender. There were also limitations. We did not examine all vaccine priority 303 groups. There was insufficient data to examine occupational vaccine priority groups such as 304 healthcare workers, though it would be valuable to gain insights into vaccination coverage 305 and hesitancy in these groups who were also eligible to receive the vaccine. We only 306 examined two broad age groups because there were too few younger people in the priority 307 groups to disaggregate the age groups further. As a result, we could not examine people aged 308 younger than 50 years separately, for whom there were different recommendations for use of 309 the Cominraty (Pfizer/BioNTech) vaccine. Further, due to the age categories used in the 310 survey, it was not possible to identify people aged 70 years and above to align with age-based 311 eligibility. We did not examine differences by other socio-demographic characteristics 312 including ethnicity, Aboriginal and Torres Strait Islander peoples, or cultural and linguistic 313 diversity because the survey did not collect data on these characteristics. Given the evidence 314 about differences in vaccine hesitancy by ethnicity in the United Kingdom and the Unites States<sup>28</sup> but not found in New Zealand<sup>29</sup> it is important to examine differences in vaccine 315 316 hesitancy according to ethnicity for people in priority groups in future research. Participation 317 rates could not be estimated in this study, therefore it was not possible to assess the impact of 318 potential selection bias from non-participation. Due to its relatively small sample, the survey 319 is unlikely to be representative of the Australian population, though the sample weights make 320 the results more representative of the population. The vaccine coverage was estimated to be 321 8.2% overall, which is broadly consistent, though perhaps slightly lower, than population estimates of vaccination coverage at similar time points, estimated to be 7.5% on 25<sup>th</sup> April 322 2021 and 12.1% on 16<sup>th</sup> May 2021.<sup>30</sup> 323

- 324
- 325

### 326 Conclusions

327 This study highlights the lack of a difference in vaccination coverage in the first few months 328 of Australia's COVID-19 vaccination program between people with disability and long-term 329 health conditions who were prioritised in the COVID-19 vaccination program and the general 330 population. The results are concerning because low vaccination coverage for people in the 331 priority population groups leaves many people at significant risk of serious disease or death if 332 exposed to COVID-19, particularly in light of the easing of disease-control restrictions across 333 Australia once population vaccination targets were achieved and the emergence of new 334 COVID-19 variants.

335

Recent data are needed to analyse current inequalities in vaccination coverage between people with disability and long-term health conditions compared to the overall population statistics to contrast the results from the start of the vaccination program with the current situation in which Australia has reached high vaccination coverage in the population overall. Furthermore, data should be routinely collected to report on vaccination coverage for people with disability and long-term health conditions.

342

343 Vaccine hesitancy was found to be similar between people with disability and long-term 344 health conditions compared to the overall sample, suggesting that low vaccination coverage is 345 likely to be caused by barriers to accessing vaccination rather than high vaccine hesitancy. 346 There remains a lack of understanding of the barriers faced by people in these priority 347 groups. Further research is needed to understand the barriers to accessing COVID-19 348 vaccination experienced by Australians with disability and long-term health condition, to 349 generate the information that is needed to devise effective strategies to improve uptake by 350 ensuring these populations have easy access to COVID-19 vaccines such as accessible 351 vaccination hubs, in-reach into workplaces and homes, and co-designed communication 352 strategies.

353

#### 354 Authors' contributions

355 ZA, AK and EE conceived the study and designed the questions for the TTPN Survey. ZA

analysed the data and results were reviewed and interpreted by ZA, AK and EE. ZA and AK

357 wrote the manuscript, which was reviewed by EE.

358

## 359 **Conflict of interest statement**

360 The authors have no conflicts of interest.

361

#### 362 Funding

363 This study was funded by a National Health and Medical Research Council Centre of

364 Research Excellence grant (1116385). The funders of the study had no role in the design of

the study, data collection, data analysis, data interpretation, or writing of the manuscript.

366

### 367 Ethics committee approval

- 368 The Taking the Pulse of the Nation Survey was approved by the Human Research Ethics
- 369 Committee at the University of Melbourne (2021-14006-14669-1).

# 370 **References**

371	1. World Health Organization. WHO SAGE roadmap for prioritizing the use of COVID-19
372	vaccines in the context of limited supply: an approach to inform planning and subsequent
373	recommendations based upon epidemiologic setting and vaccine supply scenarios. CC BY-
374	NC-SA 3.0 IGO. Geneva: World Health Organization, 2020.
375	2. Commonwealth Department of Health. Australia's COVID-19 vaccine national roll-
376	out strategy 2020.
370	https://www.health.gov.au/sites/default/files/documents/2021/01/covid-19-vaccination-
378	
	australia-s-covid-19-vaccine-national-roll-out-strategy.pdf.
379 380	3. Johns Hopkins Coronavirus Resource Centre. Vaccination progress across the world. 2021. <u>https://coronavirus.jhu.edu/vaccines/international</u> (accessed 04/08/2021 2021).
381	<ol> <li>Australian Government Operation COVID Shield. COVID-19 Vaccine Rollout, 15</li> </ol>
382	February 2022. 2022.
382	https://www.health.gov.au/sites/default/files/documents/2022/02/covid-19-vaccine-
383	rollout-update-15-february-2022.pdf (accessed 15 February 2022 2022).
385	5. Bedford H, Attwell K, Danchin M, Marshall H, Corben P, Leask J. Vaccine hesitancy,
386	refusal and access barriers: The need for clarity in terminology. <i>Vaccine</i> 2018; <b>36</b> (44): 6556-
387 388	<ol> <li>Sabatello M, Landes SD, McDonald KE. People With Disabilities in COVID-19: Fixing</li> </ol>
389	Our Priorities. The American Journal of Bioethics 2020; <b>20</b> (7): 187-90.
390	7. Boyle CA, Fox MH, Havercamp SM, Zubler J. The public health response to the
391	COVID-19 pandemic for people with disabilities. <i>Disability and Health Journal</i> 2020; <b>13</b> (3):
392	100943.
393	8. Clay L. Two-thirds of staff in aged care homes not vaccinated. The Age. 2021
394 205	26/06/2021.
395 206	9. Henriques-Gomes L. 'Abject failure': only 999 out of 26,000 Australian disability care
396	residents vaccinated. The Guardian. 2021 17/05/2021.
397	10. Senator the Hon Linda Reynolds CSC. NDIS COVID-19 vaccine rollout update [press
398	release]: Ministers for the Department of Social Services, 2021.
399 400	11. Australian Government Operation COVID Shield. COVID-19 Vaccine Rollout, 21
400	January 2022. 2022.
401	https://www.health.gov.au/sites/default/files/documents/2022/01/covid-19-vaccine-
402	rollout-update-21-january-2022.pdf (accessed 15 February 2022 2022).
403	12. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic
404	Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. <i>N Engl J Med</i> 2021; <b>384</b> (22): 2092-
405	
406	13. Schultz NH, Sorvoll IH, Michelsen AE, et al. Thrombosis and Thrombocytopenia after
407	ChAdOx1 nCoV-19 Vaccination. <i>N Engl J Med</i> 2021; <b>384</b> (22): 2124-30.
408	14. MacDonald NE, Sage Working Group on Vaccine Hesitancy. Vaccine hesitancy:
409	Definition, scope and determinants. <i>Vaccine</i> 2015; <b>33</b> (34): 4161-4.
410	15. Dror AA, Eisenbach N, Taiber S, et al. Vaccine hesitancy: the next challenge in the
411	fight against COVID-19. Eur J Epidemiol 2020; <b>35</b> (8): 775-9.
412	16. Ipsos. Global attitudes: COVID-19 vaccines. 2021. <u>https://www.ipsos.com/en-</u>
413	ba/global-attitudes-covid-19-vaccine-january-2021 (accessed 09/02/2021 2021).
414	17. Biddle N, Edwards B, Gray M, Sollis K. Change in vaccine willingness in Australia:
415	August 2020 to January 2021. medRxiv 2021: 2021.02.17.21251957.
416	18. ABS. People with disability: Household impacts of COVID-19. Canberra: ABS, 2022.

417 19. Butler R, MacDonald NE. Diagnosing the determinants of vaccine hesitancy in

- 418 specific subgroups: The Guide to Tailoring Immunization Programmes (TIP). *Vaccine* 2015; 419 **33**(34): 4176-9.
- 420 Strully KW, Harrison TM, Pardo TA, Carleo-Evangelist J. Strategies to Address COVID-20. 421 19 Vaccine Hesitancy and Mitigate Health Disparities in Minority Populations. Front Public
- 422 Health 2021; 9: 645268.
- 423 Cesar CC, Carvalho MS. Stratified sampling design and loss to follow-up in survival 21. 424 models: evaluation of efficiency and bias. BMC Med Res Methodol 2011: **11**: 99.
- 425 22. ABS. National, state and territory population. Canberra: ABS, 2021.
- 426 23. MacDonald NE, Hesitancy SWGoV. Vaccine hesitancy: Definition, scope and 427
- determinants. Vaccine 2015; 33(34): 4161-4.
- 428 Royal Commission into Violence, Abuse, Neglect and Exploitation of People with 24. 429 Disability. Public hearing 12: The experiences of people with disability, in the context of the
- 430 Australian Government's approach to the COVID 19 vaccine rollout. Sydney, 2021.
- 431 25. Australian Government Operation COVID Shield. COVID-19 Community Sentiment 432 Monitor: Summary (Jan-22). 2022.
- 433 https://www.health.gov.au/sites/default/files/documents/2022/02/operation-covid-shield-
- 434 covid-19-vaccine-sentiment-summary-january-2022-covid-19-community-sentiment-
- 435 monitor-summary-january-2022 0.pdf (accessed 17 February 2022 2022).
- 436 26. People with Disability Australia. People With Disability Struggle To Access COVID
- 437 Vaccine. 2021. https://pwd.org.au/people-with-disability-struggle-to-access-covid-vaccine/ 438 (accessed 17 February 2022 2022).
- Gearin M. People with disabilities facing multiple barriers in Australia's coronavirus 439 27. 440 vaccine rollout. ABC News. 2021 21 May 2021.
- 441 28. Khan MS, Ali SAM, Adelaine A, Karan A. Rethinking vaccine hesitancy among minority 442 groups. Lancet 2021; 397(10288): 1863-5.
- 443 29. Prickett KC, Habibi H, Carr PA. COVID-19 Vaccine Hesitancy and Acceptance in a
- 444 Cohort of Diverse New Zealanders. Lancet Reg Health West Pac 2021; 14: 100241.
- 445 30. Commonwealth Department of Health. COVID-19 vaccine rollout updates. . 2021.
- 446 https://www.health.gov.au/resources/collections/covid-19-vaccine-rollout-updates.
- 447